Autopsy report · NCT00510289
Sorafenib in Myelodysplastic Syndrome
Cause of deathSlow enrollment
“Early closure of study due to poor response”
Life of this trial
- Registered 1 year after it had already started.
- Ran for about 5 years before it stopped.
- 19 participants enrolled.
- Results were posted on the registry 2 years 7 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Duke University
- Sponsor type
- University, hospital or other
- Conditions
- Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic
- Interventions
- Sorafenib
- Participants
- 19
- Sites
- 1
- Countries
- United States
Trials that died the same way
- A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
“Study closed due to slow accrual and lack of efficacy.” - S0002 - A Program to Quit Smoking With or Without Bupropion in Treating Patients With Stage I or II Non-Small Cell Lung Cancer Who Have Undergone Surgery
“This study was closed early due to poor accrual” - High Dose Rate Brachyablation of Primary Liver Lesions
“Study was closed due to poor accrual” - Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
“This study was closed to enrollment as of 13 May 2011 due to business reasons. Premature closure was not prompted by any safety or efficacy concerns.” - A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
“Study stopped early due to low patient accrual.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.